Table 1.
Differentially Expressed Genes Among APOE ε2/ε3 Subjects
| Gene |
APOE ε2/ε3 |
APOE ε3/ε3 |
APOE ε3/ε4 |
Total |
||||
|---|---|---|---|---|---|---|---|---|
| Z | P-value | Z | P-value | Z | P-value | Z | P-value | |
| C4A | 4.28 | 1.9x10−5 | 2.78 | 5.4x10−3 | 2.48 | 0.01 | 5.73 | 1.0x10−8 |
| C4B | 4.10 | 4.2x10−5 | 3.50 | 4.7x10−4 | 2.17 | 0.03 | 6.08 | 1.2x10−9 |
| GFAP | 4.12 | 3.8x10−5 | 4.03 | 5.6x10−5 | 1.51 | 0.13 | 6.89 | 5.4x10−12 |
| NPNT | 3.65 | 2.6x10−4 | 6.34 | 2.4x10−10 | 1.58 | 0.11 | 8.58 | 9.3x10−18 |
Gene expression levels were compared between AD and control brains separately in the ROSMAP, MAYO, and FHS/BUADC datasets, and results were combined by meta-analysis.
Selected genes surpassed significance thresholds p<10−3 in the APOE 2/ε3 group and p<10−6 in the total sample.